Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Angel

Showing results (191-200 of 213) with videos related to

Pageof 22
Sort By:
Journal of the International Association of Providers of AIDS Care|May 10, 2017
Exploring the Factors Considered by People Living with HIV and Their Partners during PreconceptionV Logan Kennedy, Micaela Collins, Mark H Yudin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 12, 2016
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJeffrey M Jacobson, Jean-Pierre Routy, Seth Welles, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
European Cytokine Network|June 28, 2007
Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjectsGregory B Pott, Carrie A Sailer, Reuven Porat, et al.
Human Reproduction (Oxford, England)|September 2, 2022
17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeaeSeung Gee Lee, Wongsakorn Kiattiburut, Thitiporn Khongkha, et al.
Current HIV Research|September 6, 2023
Donating One's Body to HIV Cure Research Through Canadian Medical Assistance in Dying: A Case StudyDavid Lessard, Bertrand Lebouché, André Morneau, et al.
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 29, 2025
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M StudySusan L Ford, Franco Felizarta, Kelong Han, et al.
Ebiomedicine|March 4, 2021
LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapyDelphine Planas, Amélie Pagliuzza, Rosalie Ponte, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 10, 2011
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structuresMansoureh Hakimi, Thirumahal Selvanantham, Erika Swinton, et al.
Pageof 22

Showing results (191-200 of 213) with videos related to

Sort By:
Pageof 22
Journal of the International Association of Providers of AIDS Care|May 10, 2017
Exploring the Factors Considered by People Living with HIV and Their Partners during PreconceptionV Logan Kennedy, Micaela Collins, Mark H Yudin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 12, 2016
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJeffrey M Jacobson, Jean-Pierre Routy, Seth Welles, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
European Cytokine Network|June 28, 2007
Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjectsGregory B Pott, Carrie A Sailer, Reuven Porat, et al.
Human Reproduction (Oxford, England)|September 2, 2022
17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeaeSeung Gee Lee, Wongsakorn Kiattiburut, Thitiporn Khongkha, et al.
Current HIV Research|September 6, 2023
Donating One's Body to HIV Cure Research Through Canadian Medical Assistance in Dying: A Case StudyDavid Lessard, Bertrand Lebouché, André Morneau, et al.
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 29, 2025
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M StudySusan L Ford, Franco Felizarta, Kelong Han, et al.
Ebiomedicine|March 4, 2021
LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapyDelphine Planas, Amélie Pagliuzza, Rosalie Ponte, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 10, 2011
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structuresMansoureh Hakimi, Thirumahal Selvanantham, Erika Swinton, et al.
Pageof 22